Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Aytu Biopharma Inc is a drug manufacturers-specialty & generic business based in the US. Aytu Biopharma shares (AYTU) are listed on the NASDAQ and all prices are listed in US Dollars. Aytu Biopharma employs 175 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Guided investing
Our top pick for
Building a portfolio
Our top pick for
Beginners
| Latest market close | $1.28 |
|---|---|
| 52-week range | $1.31 - $11.76 |
| 50-day moving average | $1.80 |
| 200-day moving average | $3.77 |
| Wall St. target price | $17.50 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-4.07 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.28 from 2022-01-18
| 1 week (2022-01-11) | -11.11% |
|---|---|
| 1 month (2021-12-17) | -20.00% |
| 3 months (2021-10-18) | -49.61% |
| 6 months (2021-07-19) | -69.30% |
| 1 year (2021-01-19) | -83.29% |
|---|---|
| 2 years (2020-01-17) | 60.00% |
| 3 years (2019-01-18) | 21.90% |
| 5 years (2017-01-19) | 15.32% |
| Revenue TTM | $74 million |
|---|---|
| Gross profit TTM | $29.2 million |
| Return on assets TTM | -14.54% |
| Return on equity TTM | -80.8% |
| Profit margin | -110.57% |
| Book value | $4.02 |
| Market capitalisation | $38 million |
TTM: trailing 12 months
We're not expecting Aytu Biopharma to pay a dividend over the next 12 months.
Aytu Biopharma's shares were split on a 1:10 basis on 8 December 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aytu Biopharma shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Aytu Biopharma shares which in turn could have impacted Aytu Biopharma's share price.
Over the last 12 months, Aytu Biopharma's shares have ranged in value from as little as $1.31 up to $11.76. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aytu Biopharma's is -0.3654. This would suggest that Aytu Biopharma's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Aytu Biopharma has bucked the trend.
Aytu Biopharma, Inc. , a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021.
Donut earns up to 10% APY, but you must have an iOS device.
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
